Literature DB >> 18508237

125I seed implant brachytherapy-assisted surgery with preservation of the facial nerve for treatment of malignant parotid gland tumors.

J Zhang1, J G Zhang, T L Song, L Zhen, Y Zhang, K H Zhang, Z H Yang, G Y Yu.   

Abstract

The surgical treatment of malignant parotid gland tumors combined with (125)I seed implant brachytherapy and preservation of the facial nerve is described. Tumor and parotid gland resection with preservation of the facial nerve was carried out in 12 patients with malignant parotid gland tumors. (125)I seeds were implanted into the target area intra- or postoperatively. The extent of regional control of the tumor was followed up, and facial nerve function was evaluated. None of the patients had tumor recurrence during the follow-up period of 50-74 months (median follow-up period, 66 months). Facial nerve function had recovered to normal by 6 months postoperatively in all patients. A limited surgical resection combined with (125)I seed implant brachytherapy is therefore considered to be an alternative treatment for local control of malignant parotid gland tumors with preservation of the facial nerve.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508237     DOI: 10.1016/j.ijom.2008.04.013

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  13 in total

1.  [2014: activation of OPS 8-980 "Complex intensive care treatment" by DIMDI].

Authors:  L Engelmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-12-20       Impact factor: 0.840

2.  125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.

Authors:  M-W Huang; L Zheng; S-M Liu; Y Shi; J Zhang; G-Y Yu; J-G Zhang
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

3.  Postoperative [¹²⁵I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland: with associated risk factors.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Jie Zhang; Lei Zheng; Shu-Ming Liu; Ming-Wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-04-29       Impact factor: 3.621

4.  Inhibition of glioblastoma growth and invasion by 125I brachytherapy in rat glioma model.

Authors:  Feihong Chen; Dan Wang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

5.  The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy: incidence of radioepidermitis and the dose-response relationship.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Lei Zheng; Hong Gao; Jie Zhang; Shu-ming Liu; Ming-wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-09-09       Impact factor: 3.621

6.  125I seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents.

Authors:  L Zheng; J Zhang; T Song; J Zhang; G Yu; Y Zhang
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

7.  RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro.

Authors:  Xiaohua Liu; Yincheng Zhang; Wenhao Ren; Tengteng Cao; Yongjin Zhu
Journal:  J Biomed Res       Date:  2010-05

8.  A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck.

Authors:  Ming-Wei Huang; Shu-Ming Liu; Lei Zheng; Yan Shi; Jie Zhang; Yan-Sheng Li; Guang-Yan Yu; Jian-Guo Zhang
Journal:  J Radiat Res       Date:  2012-08-01       Impact factor: 2.724

9.  Clinical application of computed tomography-guided (125)I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases.

Authors:  Hai Huang; Shaonian Xu; Fusheng Li; Zhenguang Du; Liang Wang
Journal:  Eur J Med Res       Date:  2016-04-27       Impact factor: 2.175

10.  The efficacy of iodine-125 permanent brachytherapy versus intensity-modulated radiation for inoperable salivary gland malignancies: study protocol of a randomised controlled trial.

Authors:  Shu-Ming Liu; Hai-Bo Wang; Yan Sun; Yan Shi; Jie Zhang; Ming-Wei Huang; Lei Zheng; Xiao-Ming Lv; Bao-Min Zheng; Kathleen H Reilly; Xiao-Yan Yan; Ping Ji; Yang-Feng Wu; Jian-Guo Zhang
Journal:  BMC Cancer       Date:  2016-03-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.